Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 1400-1404, May 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Driedger, P. E.
Right arrow Articles by Blumberg, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Driedger, P. E.
Right arrow Articles by Blumberg, P. M.

Different Biological Targets for Resiniferatoxin and Phorbol 12-Myristate 13-Acetate1

Paul E. Driedger2 and Peter M. Blumberg3

Department of Pharmacology, Harvard Medical School, Boston, Massachusetts 02115

The phorbol-related diterpene ester resiniferatoxin is at least 100-fold more inflammatory for the mouse ear than is the potent tumor promoter phorbol 12-myristate 13-acetate but is nonpromoting. We report here that resiniferatoxin is 100- to 1000-fold less active than is phorbol 12-myristate 13-acetate in in vitro assays with both chicken and mouse fibroblasts. These results suggest that resiniferatoxin and phorbol 12-myristate 13-acetate have different primary target sites (receptors) and provide further evidence that the fibroblast target may be homologous to that involved in promotion.

1 This research was supported by Grant CA-22895 from the NIH.

2 Predoctoral Fellow of the Pharmaceutical Manufacturers Association.

3 Fellow of the Medical Foundation, Boston. To whom requests for reprints should be addressed.

Received 7/30/79. Accepted 1/24/80.




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
K. Sugimoto, I. Kissin, and G. Strichartz
A High Concentration of Resiniferatoxin Inhibits Ion Channel Function in Clonal Neuroendocrine Cells
Anesth. Analg., July 1, 2008; 107(1): 318 - 324.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Szallasi and P. M. Blumberg
Vanilloid (Capsaicin) Receptors and Mechanisms
Pharmacol. Rev., June 1, 1999; 51(2): 159 - 212.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.